Clinical Trials Logo

Systemic Inflammatory Process clinical trials

View clinical trials related to Systemic Inflammatory Process.

Filter by:
  • None
  • Page 1

NCT ID: NCT01351805 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

VITAL
Start date: July 2010
Phase: N/A
Study type: Interventional

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 25,871 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. This ancillary study is being conducted among VITAL participants and will examine whether vitamin D or fish oil have effects upon A) autoimmune disease incidence, B) biomarkers of systemic inflammation, and C) chronic knee pain. Blood samples at baseline and in follow-up will be collected in a randomly selected subcohort of 1500 individuals and analyzed for changes in biomarkers of systemic inflammation: C-reactive protein, interleukin-6, and tumor necrosis factor-receptor 2. Approximately 1300 individuals with chronic, frequent knee pain will be followed with annual questionnaires to evaluate the effects of the supplements on chronic knee pain.

NCT ID: NCT01349699 Completed - Anemia Clinical Trials

Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia

Start date: February 2010
Phase: N/A
Study type: Interventional

Iron affects immunity. However, the exact effect of iron on the innate immune response is not known. Animal data suggest that iron administration induced oxidative stress which enhances the innate immune response, whereas iron chelation has the opposite effect. The investigators tested the hypothesis that administration of iron sucrose 1.25 mg/kg augments the innate immune response, and iron chelation by deferasirox 30 mg/kg attenuates the innate immune response during human experimental endotoxemia.